Mikami Hironobu, Ishimura Norihisa, Fukazawa Kousuke, Okada Mayumi, Izumi Daisuke, Shimura Shino, Okimoto Eiko, Aimi Masahito, Ishihara Shunji, Kinoshita Yoshikazu
Second Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
Department of Gastroenterology and Hepatology, Kasai City Hospital, Kasai, Japan.
J Neurogastroenterol Motil. 2016 Jan 31;22(1):112-7. doi: 10.5056/jnm15130.
BACKGROUND/AIMS: Prokinetic drugs such as metoclopramide are frequently used as second-line therapy for patients with gastroesophageal reflux disease. However, their beneficial effects remain unclear. Esophageal motor activities and compliance of the esophagogastric junction (EGJ) are important for prevention of gastroesophageal reflux. Although metoclopramide has been reported to increase lower esophageal sphincter (LES) pressure, its effects on EGJ compliance have not been evaluated. In the present study, we investigated the effects of metoclopramide on esophageal motor activities and EGJ compliance.
Nine healthy male volunteers without abdominal symptoms were enrolled. Peristaltic esophageal contractions and LES pressure were examined using high-resolution esophageal manometry, while EGJ compliance was evaluated with an endoluminal functional lumen-imaging probe. After obtaining baseline values for esophageal motor activities and EGJ compliance, metoclopramide (10 mg) was intravenously administered, then all measurements were repeated at 15 minutes after administration in each subject.
Following administration of metoclopramide, mean resting LES pressure was significantly increased as compared with the baseline (13.7 ± 9.2 vs 26.7 ± 8.8 mmHg, P < 0.05). In addition, metoclopramide significantly augmented peristaltic contractions, especially in the distal esophageal segment (P < 0.05). On the other hand, distensibility index did not change after administration (4.5 ± 0.5 vs 4.1 ± 0.5 mm(2)/mmHg), suggesting no significant effect of metoclopramide on EGJ compliance.
Metoclopramide augmented esophageal contractions without changing EGJ compliance in healthy adults.
背景/目的:胃复安等促动力药物常被用作胃食管反流病患者的二线治疗药物。然而,其有益效果仍不明确。食管运动活动和食管胃交界处(EGJ)的顺应性对预防胃食管反流很重要。虽然据报道胃复安可增加食管下括约肌(LES)压力,但其对EGJ顺应性的影响尚未得到评估。在本研究中,我们调查了胃复安对食管运动活动和EGJ顺应性的影响。
招募9名无腹部症状的健康男性志愿者。使用高分辨率食管测压法检查食管蠕动收缩和LES压力,同时用腔内功能性管腔成像探头评估EGJ顺应性。在获得食管运动活动和EGJ顺应性的基线值后,静脉注射胃复安(10毫克),然后在每个受试者给药后15分钟重复所有测量。
给予胃复安后,平均静息LES压力与基线相比显著增加(13.7±9.2对26.7±8.8毫米汞柱,P<0.05)。此外,胃复安显著增强了蠕动收缩,尤其是在食管远端段(P<0.05)。另一方面,给药后扩张指数没有变化(4.5±0.5对4.1±0.5平方毫米/毫米汞柱),表明胃复安对EGJ顺应性没有显著影响。
在健康成年人中,胃复安增强了食管收缩而不改变EGJ顺应性。